WVP
XFOR icon

Worth Venture Partners’s X4 Pharmaceuticals XFOR Stock Holding History

Worth Venture Partners’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,338
Closed -$428K – 208
2022
Q3 		$428K Hold
8,338
– – 0.26% 78
2022
Q2 		$278K Hold
8,338
– – 0.16% 97
2022
Q1 		$438K Sell
8,338
-3,012
-27% -$173K 0.2% 86
2021
Q4 		$780K Sell
11,350
-1,533
-12% -$194K 0.39% 65
2021
Q3 		$2.04M Buy
12,883
+1,727
+15% +$284K 0.92% 38
2021
Q2 		$2.17M Buy
+11,156
New +$2.8M 0.81% 40

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Worth Venture Partners's XFOR Position: Q4 2022 in Review

Worth Venture Partners sold out of X4 Pharmaceuticals (XFOR) in Q4 2022, closing a stake of 8,338 shares — an estimated $428K sold.

Worth Venture Partners first reported a position in XFOR in Q2 2021 and held it in 6 quarters. The position peaked at $2.17M in Q2 2021. 52 funds tracked by Wall St. Rank hold XFOR as of Q4 2022.

  • Worth Venture Partners reported no remaining X4 Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Worth Venture Partners sold 8,338 X4 Pharmaceuticals shares in Q4 2022, an estimated $428K.
  • Worth Venture Partners first reported a position in X4 Pharmaceuticals in Q2 2021 and held it in 6 quarters.
  • Worth Venture Partners's X4 Pharmaceuticals position peaked at $2.17M in Q2 2021.
  • 52 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2022.

Based on Worth Venture Partners's 13F filing for Q4 2022, filed 14 Feb 2023.